![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-1.png\")
<\/p>\n<\/p>\n
DelveInsight’s <\/span>CAR T-Cell Therapy pipeline report<\/strong><\/a> gives extensive insights into the CAR T-Cell Therapy pipeline landscape, including 250+ companies and 250+ pipeline therapies. It includes clinical and nonclinical stage medicines in the pipeline medication profiles. It also examines medicines by product type, stage, administration route, and molecule type.<\/span><\/p>\n Some of the Crucial Highlights from the <\/strong>CAR T-Cell Therapy Pipeline Report<\/strong><\/a><\/p>\n To learn more, request sample @ <\/span>CAR T-Cell Therapy Clinical Trials<\/strong><\/a><\/p>\n CAR T-Cell Therapy: Overview<\/strong><\/p>\n CAR T-cells are fusion proteins made up of one or more T-cell receptor intracellular signalling domains with a single-chain fragment varying from a monoclonal antibody. <\/span><\/p>\n CAR T-Cell Therapy<\/strong><\/a> involves genetically modifying a patient’s autologous T-cells to express a CAR that recognises a tumour antigen, followed by ex vivo cell multiplication and re-infusion. CAR T-Cell Therapies are being used to treat malignancies of all kinds.<\/span><\/p>\n CAR T-Cell Therapy Pipeline Analysis: Drug Profiles <\/strong><\/p>\n JWCAR029: JW Therapeutics<\/strong><\/p>\n Product Description<\/strong><\/p>\n JWCAR029 (Relmacabtagene autoleucel) is a CAR-T cell product that targets CD19 and is being developed as a third-line treatment for relapsed or refractory (r\/r) B-cell lymphoma.<\/span><\/p>\n Phase II<\/strong><\/p>\n NCT04089215:<\/strong> In June 2019, a phase II, open-label, single-arm, multicenter research in China was launched to assess the efficacy and safety of JWCAR029 in adult R\/R Non-Hodgkin’s Lymphoma patients. This is a multicenter, phase II, open-label, single-arm research in adult individuals with R\/R Non-Hodgkin’s Lymphoma in China to assess the safety, effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of JWCAR029.<\/span><\/p>\n Get in touch to know more about the <\/span>CART T-Cell Therapy FDA Approval<\/strong><\/a><\/p>\n CAR T-Cell Therapy Pipeline Therapies and Key Companies <\/strong><\/p>\n CAR T-Cell Therapy Therapeutics Assessment<\/strong><\/a><\/p>\n Scope of the Report<\/strong><\/a><\/p>\n Coverage:<\/strong> Global<\/span><\/p>\n CAR T-Cell Therapy Key Players: <\/strong>Bluebird Bio, Cartesian Therapeutics, Autolus Limited, Novartis, BioAtla, JW Therapeutics<\/span>,<\/span> among others<\/span><\/p>\n CAR T-Cell Therapy Pipeline Therapies:<\/strong> bb21217, Descartes-08, AUTO4, CTL119, BA 3011, WCAR029,<\/span> and others<\/span><\/p>\n Table of Contents<\/strong><\/p>\n![\"CAR-T-Cell-Therapy-Pipeline-Insights\"](\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/CAR-T-Cell-Therapy-Pipeline-Insights.jpg?1628501144191\")
<\/span><\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n\n
\n 1.<\/td>\n Key Insights<\/span><\/td>\n<\/tr>\n \n 2.<\/td>\n Report Introduction<\/span><\/td>\n<\/tr>\n \n 3.<\/td>\n CAR T-Cell Therapy: Snapshot<\/span><\/td>\n<\/tr>\n \n 4.<\/td>\n CAR T-Cell Therapy: Overview<\/span><\/td>\n<\/tr>\n \n 5.<\/td>\n CAR T-Cell Therapy Pipeline Scenario<\/span><\/td>\n<\/tr>\n \n 6.<\/td>\n CAR T-Cell Therapy Pipeline Therapeutics<\/span><\/td>\n<\/tr>\n \n 7.<\/td>\n CAR T-Cell Therapy Late Stage Products (Registered)<\/span><\/td>\n<\/tr>\n \n 8.<\/td>\n CAR T-Cell Therapy Late Stage Products (Pre-registration)<\/span><\/td>\n<\/tr>\n \n 9.<\/td>\n CAR T-Cell Therapy Mid Stage Products (Phase II)<\/span><\/td>\n<\/tr>\n \n 10.<\/td>\n CAR T-Cell Therapy Early Stage Products (Phase I\/II)<\/span><\/td>\n<\/tr>\n \n 11.<\/td>\n CAR T-Cell Therapy Early Stage Products (Phase I)<\/span><\/td>\n<\/tr>\n \n 12.<\/td>\n CAR T-Cell Therapy IND-stage Products<\/span><\/td>\n<\/tr>\n \n 13.<\/td>\n CAR T-Cell Therapy Preclinical stage Products<\/span><\/td>\n<\/tr>\n \n 14.<\/td>\n CAR T-Cell Therapy Discovery stage Products<\/span><\/td>\n<\/tr>\n \n 15.<\/td>\n CAR T-Cell Therapy Therapeutic Assessment<\/span><\/td>\n<\/tr>\n \n 16.<\/td>\n CAR T-Cell Therapy Inactive Products<\/span><\/td>\n<\/tr>\n \n 17.<\/td>\n CAR T-Cell Therapy- Unmet Needs<\/span><\/td>\n<\/tr>\n \n 18.<\/td>\n CAR T-Cell Therapy- Market Drivers and Barriers<\/span><\/td>\n<\/tr>\n \n 19.<\/td>\n Appendix<\/span><\/td>\n<\/tr>\n \n 20.<\/td>\n About DelveInsight<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n